NCT05909501Recruiting

Assessment of Geriatric Evaluations Impact on New AML Guidance

Abramson Cancer Center at Penn Medicine

Start Date

10/25/2023

Completion Date

12/1/2026

Summary

The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. This information will be used to evaluate toxicity, early mortality, remission rates and long term survival.

Eligibility Criteria

Age Range: 50 years to No maximum

Inclusion Criteria: * AML diagnosis by peripheral flow cytometry and/or bone marrow aspirate and biopsy * New diagnosis being considered for new line of treatment * Age ≥ 50 years. * Performance status 0,1, and 2 Exclusion Criteria: * Inability to understand or unable to sign a written informed consent * Unable to fill out questionnaires on their own and/or do not have someone to help complete them

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

AML, Adult

Locations

Abramson Cancer Center at University of Pennsylvania

Philadelphia, Pennsylvania 19104

United States